2015 Annual Meeting On Demand: Sunday Sessions

You can earn up to 13.25 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 7 MOC Part II Self-Assessment credits.

This collection covers general sessions from Sunday's program. This includes plenaries, symposia, and, for the first time, several workshops have been included. The sessions listed below are included in this package.

  • Controversial Manifestations of Contact Dermatitis
  • Human Microbiome: The Interface of Immunology and Microbiology
  • Treatment Strategies for Children Having Both Persistent Allergic Rhinitis and Asthma
  • Severe Asthma: Persistent Challenges; New Therapies
  • W19 Living With an Itch
  • W20 SCID Newborn Screening
  • W21 Eosinophilic Esophagitis


Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 13.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Discuss the relationship between metal hypersensitivity and prosthetic joint failure
• Discuss similarities and differences in allergic reactions to cardiovascular, dental and gynecologic medical devices
• Identify other causes of dermatitis with generalized distribution such  as systemic contact dermatitis to drug, food and fragrances
• Discuss facets of modulation of gut microbiota that lead to disruption of host-microorganism homeostasis and contributes to the development of non-communicable inflammatory diseases

• Explain how gut microbiota dysbiosis contributes to aberrant immune development and the development of allergic disease and asthma
• Discuss the implications of gut microbiota modification for treatment and prevention of allergic disease and asthma
• Discuss which daily mono and combined medications and immunotherapy options are most effecitve in the pediatric population for persistent allergic rhinitis; explain what works for chronic sinusitis in the pediatric population; and debate if treatment should be different for children with or without concurrent asthma

• List the reasons that support, or lack therof, for the use of small particle size inhaled steroids in pediatric asthma; discuss the merits of nebulized vs. MDI vs. dry powder use of inhaled steroids in the pediatric patient (age 6 and older); and debate daily vs. dynamic dosing for pediatric asthmatics with "persistent" but not daily asthma symptoms
• Discuss overall safety of nasal and inhaled steroids in pediatrics; list the nasal and inhaled steroids with the best safety profile for pediatric patients; explain the published data and expert opinion on the safety of using both products confurrently in pediatric patients; and compare the safety of daily inhaled steroids over intermittent oral burst of steroids (e.g., 1-2 times/year) over a 1 to 2 year time period
• Summarize  the leading hypotheses regarding mechanisms for why severe asthma is treatment resistant 

• Discuss which patients will be appropriate candidates for new severe asthma therapies
• Discuss how to obtain new asthma therapies for their patients
• Discuss the causes of pruritus, with (including atopic dermatitis) or without a rash and the workup to seek underlying diseases; and recognize that pruritus has numerous pathways and available therapies to address itch in patients with both idiopathic pruritus and pruritus secondary to another disease 
• Recognize the important steps for implementing statewide SCID newborn screening; and discuss the basis of TREC screening, including the conditions identified by this test, and the proper next steps to be taken after an abnormal newborn screening test
• Discuss the pathophysiology and differential diagnosis of eosinophilic esophagitis (EoE) and other similar swallowing disorders; and discuss the diagnostic options and evolving treatment for EoE


Additional information

Luz S. Fonacier, MD, FACAAI -- Speaker: Baxter; Supported/Contracted Research: Baxter, Genentech, Merck

Todd A. Mahr, MD, FACAAI -- Speaker: Aerocrine, Genentech, GlaxoSmithKline, Meda, Merck, Mylan, Sanofi, Teva

Eli O. Meltzer, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, Circassia, GlaxoSmithKline, Greer, Johnson & Johnson, McNeill, Meda, Merck, Regeneron, Sanofi, Sunovion, Teva, Takeda, Valeant; Speaker: Alcon, Greer, Meda, Mylan, Sunovion, Teva, Takeda

Bobby Q. Lanier, MD, FACAAI -- Supported/Contracted Research: Merck, Novartis, Teva; Speaker: Genentech, Merck

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: GlaxoSmithKline, Meda, Mylan; Supported/Contracted Research: AstraZeneca, MedImmune, Novartis

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: GlaxoSmithKline, Meda

Peter A. Lio, MD -- Consultant/Advisor: Anacor, Galderma, Johnson & Johnson, Pierre Fabre, Valeant 

Lisa K. Kobrynski, MD, MPH, FACAAI -- Supported/Contracted Research: Baxter; Speaker: Baxter, CSL Behring

Mirna Chehade, MD, MPH -- Consultant/Advisor: Receptos

The following have no financial relationships to disclose:

Peter Schalock, MD

James S. Taylor, MD, FACAAI

David E. Cohen, MD

Michael B. Foggs, MD, FACAAI

Fernando D. Martinez, MD

Lanny J. Rosenwasser, MD, FACAAI

Yvonne Huang, MD

Dana V. Wallace, MD, FACAAI

David P. Skoner, MD, FACAAI

Kevin R. Murphy, MD, FACAAI (SC)

John M. Routes, MD, FACAAI

Jonathan M. Spergel, MD, PhD, FACAAI

Course summary
Available credit: 
  • 13.25 AMA PRA Category 1 Credit™
  • 13.25 Attendance
  • 7.00 MOC
Course opens: 
Course expires: 

Available Credit

  • 13.25 AMA PRA Category 1 Credit™
  • 13.25 Attendance
  • 7.00 MOC
Please login or create an account to take this course.